Major Tumor Markers

The National Academy of Clinical Biochemistry

Laboratory Medicine Practice Guidelines

Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Publication Date: 2009

Chinese Translation

We present to clinical chemists, clinicians, and other practitioners of laboratory and clinical medicine the latest update of the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. These guidelines are intended to encourage more appropriate use of tumor marker tests by primary care physicians, hospital physicians and surgeons, specialist oncologists, and other health professionals.

Guidelines Committee:

  • Catharine M. Sturgeon, Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
  • Michael J. Duffy, Department of Pathology and Laboratory Medicine, St Vincent’s University Hospital and UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
  • Ulf-Håkan Stenman, Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland
  • Hans Lilja, Departments of Clinical Laboratories, Urology, and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Nils Brünner, Section of Biomedicine, Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Denmark
  • Daniel W. Chan, Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD
  • Richard Babaian, Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
  • Robert C. Bast, Jr., Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX
  • Barry Dowell, Abbott Laboratories, Abbott Park, IL
  • Francisco J. Esteva, Departments of Breast Medical Oncology, Molecular and Cellular Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
  • Caj Haglund, Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland
  • Nadia Harbeck, Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, Munich, Germany
  • Daniel F. Hayes, Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
  • Mads Holten-Andersen, Section of Biomedicine, Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Denmark
  • George G. Klee, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
  • Rolf Lamerz, Department of Medicine, Klinikum of the University Munich, Grosshadern, Germany
  • Leendert H. Looijenga, Laboratory of Experimental Patho-Oncology, Erasmus MC-University Medical Center Rotterdam, and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
  • Rafael Molina, Laboratory of Biochemistry, Hospital Clinico Provincial, Barcelona, Spain
  • Hans Jørgen Nielsen, Department of Surgical Gastroenterology, Hvidovre Hospital, Copenhagen, Denmark
  • Harry Rittenhouse, Gen-Probe Inc, San Diego, CA
  • Axel Semjonow, Prostate Center, Department of Urology, University Clinic Muenster, Muenster, Germany
  • Ie-Ming Shih, Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD
  • Paul Sibley, Siemens Medical Solutions Diagnostics, Glyn Rhonwy, Llanberis, Gwynedd, UK
  • György Sölétormos, Department of Clinical Biochemistry, Hillerød Hospital, Hillerød, Denmark
  • Carsten Stephan, Department of Urology, Charité Hospital, Universitätsmedizin Berlin, Berlin, Germany
  • Lori Sokoll, Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD
  • Barry R. Hoffman, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
  • Eleftherios P. Diamandis, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
This LMPG was developed by an independent committee of the NACB. Subsequent publication of these guidelines has been supported by the Academy.